[HTML][HTML] Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease
Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer’s
disease are needed to facilitate the initial screening process of participants in disease-…
disease are needed to facilitate the initial screening process of participants in disease-…
Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum
AL Benedet, M Milą-Alomą, A Vrillon, NJ Ashton… - JAMA …, 2021 - jamanetwork.com
Importance Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease (AD). …
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease (AD). …
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ …
…, J Lantero Rodriguez, M Milą‐Alomą… - EMBO molecular …, 2020 - embopress.org
In Alzheimer’s disease (AD), tau phosphorylation in the brain and its subsequent release
into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease …
into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease …
Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
M Milą‐Alomą, G Salvadó, JD Gispert… - Alzheimer's & …, 2020 - Wiley Online Library
Introduction The biological pathways involved in the preclinical stage of the Alzheimer's
continuum are not well understood. Methods We used NeuroToolKit and Elecsys ® …
continuum are not well understood. Methods We used NeuroToolKit and Elecsys ® …
Plasma and CSF biomarkers in a memory clinic: head‐to‐head comparison of phosphorylated tau immunoassays
NJ Ashton, A Puig‐Pijoan, M Milą‐Alomą… - Alzheimer's & …, 2023 - Wiley Online Library
Introduction Direct comparisons of the main blood phosphorylated tau immunoassays in
memory clinic populations are needed to understand possible differences. Methods In the …
memory clinic populations are needed to understand possible differences. Methods In the …
CSF synaptic biomarkers in the preclinical stage of Alzheimer disease and their association with MRI and PET: a cross-sectional study
M Milą-Alomą, A Brinkmalm, NJ Ashton, H Kvartsberg… - Neurology, 2021 - AAN Enterprises
Background and Objectives To determine whether CSF synaptic biomarkers are altered in
the early preclinical stage of the Alzheimer continuum and associated with Alzheimer disease …
the early preclinical stage of the Alzheimer continuum and associated with Alzheimer disease …
[HTML][HTML] Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals
…, M Crous-Bou, N Vilor-Tejedor, M Mila-Aloma… - Environment …, 2021 - Elsevier
Background Air quality contributes to incidence of Alzheimer’s disease (AD) although the
underlying neurobiological mechanisms are unclear. This study was aimed to examine the …
underlying neurobiological mechanisms are unclear. This study was aimed to examine the …
[HTML][HTML] Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer's continuum
Purpose Glial activation is one of the earliest mechanisms to be altered in Alzheimer’s
disease (AD). Glial fibrillary acidic protein (GFAP) relates to reactive astrogliosis and can be …
disease (AD). Glial fibrillary acidic protein (GFAP) relates to reactive astrogliosis and can be …
P‐tau235: a novel biomarker for staging preclinical Alzheimer's disease
…, A Snellman, AL Benedet, M Milą‐Alomą… - EMBO Molecular …, 2021 - embopress.org
Alzheimer’s disease (AD) is characterised by a long preclinical phase. Although phosphorylated
tau (p‐tau) species such as p‐tau217 and p‐tau231 provide accurate detection of early …
tau (p‐tau) species such as p‐tau217 and p‐tau231 provide accurate detection of early …
Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease
M Milą-Alomą, M Suįrez-Calvet… - Therapeutic …, 2019 - journals.sagepub.com
Alzheimer’s disease (AD) is the most common neurodegenerative disease and its diagnosis
has classically been based on clinical symptoms. Recently, a biological rather than a …
has classically been based on clinical symptoms. Recently, a biological rather than a …